Medlab Clinical

Latest Insights

Healthcare |
Outlook

23.01.23

Medlab Clinical — NanaBis development centre stage in 2023

Healthcare |
Flash note

17.01.23

Medlab Clinical — Encouraging real-world data to support NanaBis

Healthcare |
Flash note

04.01.23

Medlab Clinical — Moving closer to the Nasdaq IPO

Healthcare |
Flash note

12.12.22

Medlab Clinical — Progressing on multiple fronts

Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (A$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	0.0	(5.7)	(52.7)
Relative	4.4	(4.0)	(49.9)
52 week high/low	A$19.5/A$6.5

Financials

Edison Investment Research is terminating coverage on Medlab Clinical (MDC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun	Revenue (A$m)	EBITDA (A$m)	PBT (A$m)	EPS (c)	P/E (x)	P/CF (x)
2021A	8.1	(11.4)	(12.4)	(627.0)	N/A	N/A
2022A	6.0	(7.4)	(8.4)	(314.0)	N/A	N/A
2023E	N/A	N/A	N/A	N/A	N/A	N/A
2024E	N/A	N/A	N/A	N/A	N/A	N/A

Research

Update

Healthcare

14.07.22

Medlab Clinical — NanaBis – now with synthetic CBD and THC

edison tv

Healthcare

09.02.22

Medlab Clinical: Edison Open House Healthcare 2022

Healthcare

Flash note

02.08.22

Medlab Clinical — FY22 cash flows within our expectations

Update

Healthcare

27.01.22

Medlab Clinical — Transforming into a pure-play biotech

edison tv

Healthcare

28.07.21

Medlab Clinical – executive interview

Initiation

Healthcare

12.07.21

Medlab Clinical — Novel drug delivery and cannabinoids against pain

QuickView

Healthcare

01.06.21

Medlab Clinical — Novel drug delivery and synthetic cannabinoids

Further insights

insight

Healthcare

09.12.22

Healthcare Week 2023

insight

Healthcare

15.02.22

Medlab Clinical: A new focus on patient suffering

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

22.03.21

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

World’s Toughest Row 2024

About Edison

About Edison

Careers

Medlab Clinical (ASX: MDC)

Latest Insights

Medlab Clinical — NanaBis development centre stage in 2023

Medlab Clinical — Encouraging real-world data to support NanaBis

Medlab Clinical — Moving closer to the Nasdaq IPO

Medlab Clinical — Progressing on multiple fronts

Sector

Balance Sheet

Share Price Performance

Financials

Research

Medlab Clinical — NanaBis – now with synthetic CBD and THC

Medlab Clinical: Edison Open House Healthcare 2022

Medlab Clinical — FY22 cash flows within our expectations

Medlab Clinical — Transforming into a pure-play biotech

Medlab Clinical – executive interview

Medlab Clinical — Novel drug delivery and cannabinoids against pain

Medlab Clinical — Novel drug delivery and synthetic cannabinoids

Further insights

Healthcare Week 2023

Medlab Clinical: A new focus on patient suffering

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time